Citations

Clear

80 citation(s) found for "Stevens, Ryan".

Personalisation and embodiment in e‐Learning for health professionals: A randomised controlled trial
Virk, Abinash , Oyen, Lance J., Cook, David A. , Skrupky, Lee P , Virk, Abinash , Cook, D A , Skrupky, Lee P. , Stevens, Ryan W. , Tande, Aaron J.

Mayo Clinic

Medical Education | September 1, 2023 | Volume: 58 | Issue: 5 | Pages: 566-574

10.1111/medu.15198 | PMID 37655515 Get It

Abstract Purpose Mayer's theory of multimedia learning proposes that personalisation and embodiment (P/E) can improve outcomes in e‐Learning. The authors hypothesised that an e‐Learning module enhanced by P/E principles would lead to higher knowledge, perceived P/E and motivation among health care professionals, compared with an unenhanced module. Methods The authors conducted a randomised trial comparing two versions of a 30‐minute multimedia e‐Learning module addressing the antibiotic management of pneumonia. The unenhanced format used slides with voiceover (human voice but no visible speaker), formal language and no specific P/E strategies. The enhanced format additionally implemented P/E strategies including conversational style, polite language, visible author, social congruence, human‐like presence and professional presence by subtly changing the script and substituting several short videos of subject matter experts. Participants included pharmacists, physicians and advanced practice providers from three academic and several community hospitals. Outcomes included knowledge, perceived P/E (assessed by the Congruence Personalisation Questionnaire, CPQ), motivation (assessed via the Instructional Materials Motivation Survey [IMMS] and Motivated Strategies for Learning Questionnaire [MSLQ]) and course satisfaction. Results There were 406 participants including 225 pharmacists, 109 physicians and 72 advanced practice providers. Post‐module knowledge was slightly higher for the enhanced versus the unenhanced format, but the difference did not reach statistical significance (adjusted mean difference, 0.04 of 10 possible, [95% CI −0.26, 0.34], p = 0.78; Cohen d 0.02). Participant perceptions of P/E (measured via CPQ) were significantly greater for the enhanced format (difference 0.46 of 5 possible [0.35, 0.56], p < 0.001; Cohen d 0.85), as were motivational features of the e‐Learning course (measured via IMMS) (difference 0.14 of 5 possible [0.02, 0.26], p = 0.02; Cohen d 0.24). Participants' overall motivational orientation (measured via MSLQ) and course satisfaction were not significantly different between the two formats ( p > 0.05). Conclusion Application of P/E principles to an e‐Learning module led to greater perceived P/E and motivational features but did not influence knowledge.
Failure of mecA/mecC PCR Testing to Accurately Predict Oxacillin Resistance in a Patient with Staphylococcus aureus Infective Endocarditis
Hess, Kyle A., Kooda, Kirstin , Shirley, Joshua D. , Schuetz, Audrey N. , Saleh, Omar Abu , Stevens, Ryan W. , Abu Saleh, Omar , Schuetz, Audrey N , Stevens, Ryan W

Mayo Clinic

Antimicrobial Agents and Chemotherapy | June 21, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00437-23 | PMID 37341623 Get It

Genotypic testing for mecA / mecC is heavily relied upon for rapid optimization of antimicrobial therapy in infections due to Staphylococcus aureus . Little is known regarding optimal reporting and/or therapy for patients demonstrating lack of genotypic evidence of mecA or mecC but phenotypic oxacillin resistance.
“How to” guide for pharmacist‐led implementation of beta‐lactam therapeutic drug monitoring in the critically ill
Ausman, Sara , Moreland-Head, Lindsay , Saleh, Omar Abu , Jannetto, Paul J. , Rivera, Christina G. , Wessel, Rebecca J , Wieruszewski, Patrick M. , Frazee, Erin N. , group, For the BLOOM Study, Ausman, Sara E , Moreland-Head, Lindsay N , Abu Saleh, Omar M, Wessel, Rebecca J , Wieruszewski, Patrick M , Frazee, Erin N , Rivera, Christina G , Stevens, Ryan W. , group, For the BLOOM Study

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | May 29, 2023 | Volume: 6 | Issue: 8 | Pages: 964-975

10.1002/jac5.1819 | PMID 37731602 Get It

AbstractBeta‐lactam therapeutic drug monitoring (TDM) can improve precision dosing and clinical outcomes in critically ill patients, but has not been implemented widely in the United States. Mayo Clinic recently implemented a beta‐lactam TDM program. This single‐center experience forms the basis of the manuscript which outlines practical considerations involved with beta‐lactam TDM implementation, including the pharmacist's role as a leader. Our implementation effort focused on three primary domains. First, we aimed to ensure a supportive organizational infrastructure. Early leadership engagement by the pharmacist‐led core team facilitated advocacy for the clinical need, allocation of resources, and assay development. Second, core clinical workflows were developed that addressed the preferred patient population for use, desirable pharmacokinetic and pharmacodynamic targets, and the preferred sampling strategy. Clinical tools to guide pharmacists in interpreting the results (e.g., pharmacokinetics calculator) and documenting decisions were developed. Third, stakeholders were offered repeated exposure to evidence and expertise to facilitate understanding and application of the new practice. This act of ‘individual internalization’ seems to be uniquely important to beta‐lactam TDM implementation compared with the implementation of other antimicrobial TDM programs. Educational strategies and supportive materials that were developed were focused on providing substantive and varied information tailored to the stakeholders' role in the process. For pharmacists, this included both clinical and operational considerations. A continuous improvement plan to support management of the process was instituted to address necessary updates and changes that inevitably emerged. In summary, the described approach to implementation of a pharmacist‐led beta‐lactam TDM program could be used as a roadmap to aid other institutions that aim to develop such a program.
Comparison of Oral and Intravenous Definitive Antibiotic Therapy for Beta-Hemolytic Streptococcus Species Bloodstream Infections from Soft Tissue Sources: a Propensity Score-Matched Analysis
Yetmar, Zachary A. , Chesdachai, Supavit , Lahr, Brian D. , Epps, Kevin , Seville, Maria Teresa , Virk, Abinash , Challener, Douglas W. , Arensman Hannan, Kellie N, Yetmar, Zachary A , Chesdachai, Supavit , Hannan, Kellie N. Arensman , Stevens, Ryan W. , Tande, Aaron J.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | May 16, 2023 | Volume: 67 | Issue: 6 | Pages: No page available

10.1128/aac.00120-23 | PMID 37191533 Get It

Beta-hemolytic streptococci are common causes of bloodstream infection (BSI). There is emerging data regarding oral antibiotics for BSI but limited for beta-hemolytic streptococcal BSI.
Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis
Adema, Jennifer L. , Ahiskali, Aileen , Hornback, Krutika Mediwala , Rivera, Christina G. , Mediwala Hornback, Krutika , Rivera, Christina G , Fida, Madiha , Stevens, Ryan W.

Mayo Clinic

Pathogens | May 12, 2023 | Volume: 12 | Issue: 5 | Pages: 703

10.3390/pathogens12050703 | PMID 37242373 Get It

Infective endocarditis (IE) is a rare but increasingly prevalent disease with high morbidity and mortality, requiring antimicrobials and at times surgical intervention. Through the decades of healthcare professionals’ experience with managing IE, certain dogmas and uncertainties have arisen around its pharmacotherapy. The introduction of new antimicrobials and novel combinations are exciting developments but also further complicate IE treatment choices. In this review, we provide and evaluate the relevant evidence focused around contemporary debates in IE treatment pharmacotherapy, including beta-lactam choice in MSSA IE, combination therapies (aminoglycosides, ceftaroline), the use of oral antimicrobials, the role of rifamycins, and long-acting lipoglycopeptides.
A Broad Spectrum of Possibilities: Spectrum Scores as a Unifying Metric of Antibiotic Utilization
Ilges, Dan , Ilges, Dan , Tande, Aaron J. , Stevens, Ryan W.

Mayo Clinic

Clinical Infectious Diseases | March 31, 2023 | Volume: 77 | Issue: 2 | Pages: 167-173

10.1093/cid/ciad189 | PMID 36999909 Get It

Abstract Days of therapy (DOT) currently serve as the standard antimicrobial utilization metric. However, by assigning the same weight to each agent rather than accounting for differences in spectrum of activity, DOT ignore key differences between agents that are fundamental to infectious diseases and critical to antimicrobial stewardship. Spectrum scoring assigns numeric values to individual antibiotic agents to quantify their spectrum of activity, allowing for the normalization of antibiotic utilization data. When used in conjunction with traditional metrics, spectrum scores may offer further clarity to antibiotic utilization; however, issues related to development, application, and standardization of spectrum scores remain. Despite these challenges, the potential applications of spectrum scores are vast. Here, we summarize existing data and explore the future of spectrum scoring, including application to both data analysis and routine patient care, use in inpatient and outpatient settings, integration within the electronic medical record, and opportunities for future research.
Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia
Hess, Kyle A., Kooda, Kirstin , Shulha, Jennifer A., Mara, Kristin C. , Mara, Kristin, Go, John R, Mara, Kristin C , Shulha, Jenny , Go, John Raymond , Fida, Madiha , DeSimone, Daniel C. , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | March 29, 2023 | Volume: 61 | Issue: 4 | Pages: No page available

10.1128/jcm.00039-23 | PMID 36988505 Get It

Antistaphylococcal penicillins (ASP) and cefazolin are first-line treatment of methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Borderline oxacillin resistance (i.e., oxacillin MICs 1-8 μg/mL) is observed in strains hyperproducing beta-lactamases.
Leptotrichia Bacteremia: 10-Year Retrospective Clinical Analysis and Antimicrobial Susceptibility Profiles
Ranganath, Nischal , Shirley, Joshua D. , Kind, Dalton R., Comba, Işın Y. , Patel, Robin , Schuetz, Audrey N. , Shah, Aditya , Challener, Douglas W. , Comba, Isin Y , Patel, Robin , Schuetz, Audrey N , Shah, Aditya S , Ranganath, Nischal , Stevens, Ryan W.

Mayo Clinic

Journal of Clinical Microbiology | January 30, 2023 | Volume: 61 | Issue: 2 | Pages: No page available

10.1128/jcm.01733-22 | PMID 36715514 Get It

Leptotrichia species are anaerobic, Gram-negative bacilli increasingly recognized as pathogens capable of causing invasive infections such as bloodstream infection (BSI), particularly among immunocompromised patients. However, there is a paucity of data regarding epidemiology, antimicrobial susceptibility, optimal treatment, and clinical outcomes among patients with Leptotrichia bacteremia.
Does metabolite matter? Defining target itraconazole and hydroxy‐itraconazole serum concentrations for blastomycosis
Firkus, Danielle , Saleh, Omar Abu , Enzler, Mark J., Jannetto, Paul J. , Mara, Kristin C. , Vergidis, Paschalis , Rivera, Christina G. , Stevens, Ryan W. , Abu Saleh, Omar M, Mara, Kristin C , Vergidis, Paschalis , Rivera, Christina G , Stevens, Ryan W

Mayo Clinic

Mycoses | January 17, 2023 | Volume: 66 | Issue: 5 | Pages: 412-419

10.1111/myc.13565 | PMID 36648362 Get It

AbstractBackgroundItraconazole is the recommended first‐line treatment for mild‐to‐moderate blastomycosis and consolidation treatment of moderate‐to‐severe disease. Itraconazole is metabolised into three metabolites, including an active metabolite hydroxy‐itraconazole. Literature provides little evidence indicating whether therapeutic drug monitoring targets should be based on itraconazole parent compound alone or a sum of itraconazole and hydroxy‐itraconazole serum concentrations.ObjectivesThis study aims to compare clinical outcomes and adverse drug events (ADEs) of combined itraconazole and hydroxy‐itraconazole concentrations versus itraconazole parent compound alone in patients with blastomycosis.Patients/MethodsThis study was a retrospective cohort review of patients ≥18 years with probable or proven Blastomyces infection who received itraconazole with at least one documented serum itraconazole concentration. The primary outcome was rate of partial or complete treatment response across three patient groups: (1) Itraconazole parent compound >1.0 mcg/ml (parent), (2) parent compound <1.0 mcg/ml, but a combined itraconazole and hydroxy‐itraconazole >1.0 mcg/ml (combined) and (3) failure to achieve a combined or parent concentration >1.0 mcg/ml (subtherapeutic) for >75% of the duration of itraconazole therapy.ResultsA total of 80 patients were included (parent = 32, combined = 36, subtherapeutic = 12). No statistically significant difference was observed for rate of partial or complete treatment response (97% parent vs 94% combined, p = .99). Significantly higher mortality due to blastomycosis was observed in patients in the subtherapeutic group (0% parent vs 3% combined vs 25% subtherapeutic, p = .01).ConclusionsThis study supports an itraconazole therapeutic target combining itraconazole and hydroxy‐itraconazole >1.0 mcg/ml for blastomycosis treatment.
Therapeutic drug monitoring following crushed administration of delayed-release posaconazole tablets via enteral feeding tubes
Stevens, Ryan W. , O’Connell, Casey, Huang, Angie, Epps, Kevin , Ilges, Dan , Epps, Kevin L, Stevens, Ryan W , Ilges, Dan

Mayo Clinic

Journal of Antimicrobial Chemotherapy | December 22, 2022 | Volume: 78 | Issue: 2 | Pages: 553-555

10.1093/jac/dkac427 | PMID 36544355 Get It